- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06865105
Estudo de terapias direcionadas para o tratamento de participantes adultos com artrite psoriática ativa
Um estudo de plataforma multicêntrico, randomizado de fase 2 de terapias direcionadas para o tratamento de indivíduos adultos com artrite psoriática ativa
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms.
The therapies being assessed in this study are risankizumab, lutikizumab, ABBV-701, and ABBV-547. In Substudy 1, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: lutikizumab monotherapy, risankizumab monotherapy or a combination therapy of lutikizumab and risankizumab. In Substudy 2, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: ABBV-701 monotherapy, risankizumab monotherapy, or a combination therapy of ABBV-701 and risankizumab. In Substudy 3, participants will be randomized in a 1:1:1 ratio to one of three doses of ABBV-547. Around 300 participants will be enrolled in the study at approximately 110 sites worldwide.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: ABBVIE CALL CENTER
- Número de telefone: 844-663-3742
- E-mail: abbvieclinicaltrials@abbvie.com
Locais de estudo
-
-
Quebec
-
Sherbrooke, Quebec, Canadá, J1G 2E8
- Recrutamento
- Centre Hospitalier Universite De Sherbrooke - Hotel-Dieu Hospital /ID# 273715
-
Trois-Rivières, Quebec, Canadá, G9A 3X2
- Recrutamento
- Centre de Recherche Musculo-Squelettique /ID# 274397
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canadá, S7H 0P4
- Recrutamento
- Dr. Latha Naik Medical Professional Corporation /ID# 272803
-
-
-
-
California
-
Huntington Beach, California, Estados Unidos, 92648-5994
- Recrutamento
- Newport Huntington Medical Group /ID# 272764
-
Contato:
- Site Coordinator
- Número de telefone: 714-923-7112
-
-
Florida
-
Avon Park, Florida, Estados Unidos, 33825
- Recrutamento
- Highlands Advanced Rheumatology And Arthritis Center - Avon Park /ID# 273085
-
Contato:
- Site Coordinator
- Número de telefone: 863-314-8555
-
Clearwater, Florida, Estados Unidos, 33765
- Recrutamento
- Clinical Research Of West Florida - Phase I Unit /ID# 273198
-
Orlando, Florida, Estados Unidos, 32819
- Recrutamento
- HMD Research LLC /ID# 273086
-
Tamarac, Florida, Estados Unidos, 33321
- Recrutamento
- West Broward Rheumatology Associates /ID# 272892
-
Tampa, Florida, Estados Unidos, 33606
- Recrutamento
- Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 273199
-
Contato:
- Site Coordinator
- Número de telefone: (813) 870-1292
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Recrutamento
- Northwestern Medicine - Northwestern Memorial Hospital /ID# 275469
-
Skokie, Illinois, Estados Unidos, 60076
- Concluído
- Clinic Of Dr. Robert Hozman/Clinical Investigation Specialists, Inc /ID# 272879
-
Willowbrook, Illinois, Estados Unidos, 60527
- Recrutamento
- Willow Rheumatology and Wellness /ID# 277354
-
-
Maryland
-
Cumberland, Maryland, Estados Unidos, 21502
- Concluído
- Klein & Associates /ID# 272829
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos, 03756
- Recrutamento
- Dartmouth-Hitchcock Medical Center /ID# 272702
-
Contato:
- Site Coordinator
- Número de telefone: 603-650-4717
-
-
Ohio
-
Middleburg Heights, Ohio, Estados Unidos, 44130
- Recrutamento
- Paramount Medical Research and Consulting /ID# 272757
-
-
Pennsylvania
-
Duncansville, Pennsylvania, Estados Unidos, 16635
- Recrutamento
- Altoona Center For Clinical Research /ID# 272593
-
Contato:
- Site Coordinator
- Número de telefone: 814-296-6108
-
-
Tennessee
-
Memphis, Tennessee, Estados Unidos, 38119
- Recrutamento
- Private Practice - Dr. Ramesh C. Gupta /ID# 272897
-
-
Texas
-
Austin, Texas, Estados Unidos, 78745
- Recrutamento
- Tekton Research - West Gate /ID# 272765
-
Frisco, Texas, Estados Unidos, 75035
- Recrutamento
- Arthritis and Rheumatology Research Institute - Frisco /ID# 277306
-
Houston, Texas, Estados Unidos, 77089-6142
- Recrutamento
- Accurate Clinical Research - Houston /ID# 272754
-
San Antonio, Texas, Estados Unidos, 78251
- Recrutamento
- Tekton Research, LLC /ID# 272901
-
Tomball, Texas, Estados Unidos, 77375
- Recrutamento
- DM Clinical Research - Tomball /ID# 272760
-
-
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, França, 06001
- Recrutamento
- Centre Hospitalier Universitaire de Nice - Hopital Pasteur /ID# 272771
-
-
Auvergne-Rhône-Alpes
-
Caluire-et-Cuire, Auvergne-Rhône-Alpes, França, 69300
- Recrutamento
- Infirmerie Protestante De Lyon /ID# 273731
-
-
Indre-et-Loire
-
Chambray-lès-Tours, Indre-et-Loire, França, 37170
- Recrutamento
- Centre Hospitalier Regional Universitaire De Tours - Hopital Trousseau /ID# 272762
-
-
Loiret
-
Orléans, Loiret, França, 45067
- Concluído
- Centre Hospitalier Regional d Orleans - Hopital de la Source /ID# 272877
-
-
New Aquitaine
-
Bordeaux, New Aquitaine, França, 33076
- Concluído
- Chu Bordeaux - Hopital Pellegrin /ID# 273390
-
-
-
-
-
Budapest, Hungria, 1027
- Recrutamento
- Revita Reumatologiai Rendelo (Revita Kft.) /ID# 272857
-
Budapest, Hungria, 1023
- Recrutamento
- Semmelweis Egyetem Reumatologiai es Immunologiai Klinika /ID# 273195
-
-
Borsod-Abauj Zemplen county
-
Miskolc, Borsod-Abauj Zemplen county, Hungria, 3529
- Recrutamento
- Borsod-Abauj-Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktatokorhaz /ID# 272572
-
-
Fejér
-
Székesfehérvár, Fejér, Hungria, 8000
- Recrutamento
- Complex Rendelo Med Zrt. /ID# 272570
-
Veszprém, Fejér, Hungria, 8200
- Recrutamento
- Vital-Medicina /ID# 272855
-
-
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polônia, 85-068
- Recrutamento
- Medicover Integrated Clinical Services - Bydgoszcz (SMO/Network/Consortium) /ID# 273297
-
-
Masovian Voivodeship
-
Pruszków, Masovian Voivodeship, Polônia, 05-800
- Recrutamento
- MCBK S.C. Iwona Czajkowska Anna Podrazka-Szczepaniak /ID# 273305
-
Warsaw, Masovian Voivodeship, Polônia, 02-665
- Recrutamento
- Centrum Medyczne Reuma Park /ID# 273301
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Polônia, 15-351
- Concluído
- Osteo Medic s.c. Artur Racewicz Jerzy Supronik /ID# 273304
-
-
Warmian-Masurian Voivodeship
-
Elblag, Warmian-Masurian Voivodeship, Polônia, 82-300
- Concluído
- Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka /ID# 273306
-
-
-
-
-
Uherské Hradiště, Tcheca, 686 01
- Recrutamento
- Medical Plus Research /ID# 272363
-
Zlín, Tcheca, 760 01
- Recrutamento
- PV Medical Services /ID# 272368
-
-
Brno-mesto
-
Brno, Brno-mesto, Tcheca, 638 00
- Recrutamento
- Revmatologie /ID# 272367
-
-
Moravian-Silesian Region
-
Hlučín, Moravian-Silesian Region, Tcheca, 748 01
- Recrutamento
- L.K.N. Arthrocentrum /ID# 272366
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Participant is willing and able to comply with procedures required in the Master Protocol and relevant, actively enrolling substudies.
- Participant has a documented clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) at Screening Visit.
- Participant has active disease defined as greater than or equal to 3 tender joints (based on 68 joint count) and greater than or equal to 3 swollen joints (based on 66 joint count) at both the Screening Visit and Baseline Visit.
- Participant has active plaque PsO, with at least one psoriatic plaque of >= 2 cm diameter or nail changes consistent with PsO at Screening Visit.
- Participant must demonstrate intolerance or inadequate response to 1 to 2 targeted therapies (biologic or targeted synthetic disease-modifying antirheumatic drugs) approved for the treatment of PsA
Exclusion Criteria:
- Participants who have had major surgery performed within 12 weeks prior to randomization or plan to have a major surgery during conduct of the study (e.g., aneurysm removal, stomach ligation).
- Participants with the following active, chronic, or recurring infections: Are infected with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus(HCV) infection, active tuberculosis(TB)
- Active skin disease other than psoriasis (PsO) which could interfere with the assessment of PsO.
- History of fibromyalgia, any arthritis with onset prior to age 17 years, or current diagnosis of inflammatory joint disease other than psoriatic arthritis (PsA) (including but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus).
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Substudy 1: Risankizumab Monotherapy
Participants will receive risankizumab |
Subcutaneous (SC) Injection |
|
Experimental: Substudy 1: Lutikizumab Monotherapy
Participants will initially receive lutikizumab Dose A followed by Lutikizumab Dose B every other week. |
Subcutaneous (SC) Injection |
|
Experimental: Substudy 1: Lutikizumab and Risankizumab Combination Therapy
Participants will be administered lutikizumab and risankizumab at the same time following the same dosing regimen as the monotherapy arms. |
Subcutaneous (SC) Injection Subcutaneous (SC) Injection |
|
Experimental: Substudy 2: ABBV-701 Monotherapy
Participants will initially receive ABBV-701. |
Subcutaneous (SC) Injection |
|
Experimental: Substudy 2: Risankizumab Monotherapy
Participants will receive risankizumab. |
Subcutaneous (SC) Injection |
|
Experimental: Substudy 2: ABBV-701 and Risankizumab Combination Therapy
Participants will be administered ABBV-701 and risankizumab at the same time following the same dosing regimen as the monotherapy arms. |
Subcutaneous (SC) Injection Subcutaneous (SC) Injection |
|
Experimental: Substudy 3: ABBV-547 Dose A
Participants will receive ABBV-547 Dose A. |
Subcutaneous (SC) Injection |
|
Experimental: Substudy 3: ABBV-547 Dose B
Participants will receive ABBV-547 Dose B. |
Subcutaneous (SC) Injection |
|
Experimental: Substudy 3: ABBV-547 Dose C
Participants will receive ABBV-547 Dose C. |
Subcutaneous (SC) Injection |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
Prazo: At Week 16
|
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria:
|
At Week 16
|
|
Number of Participants With Adverse Events (AEs)
Prazo: Up to Week 52
|
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. |
Up to Week 52
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage of Participants Achieving Minimal Disease Activity (MDA) Response
Prazo: At Week 16
|
A participant was classified as achieving MDA if 5 of the following 7 criteria were met:
|
At Week 16
|
|
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
Prazo: At Week 16
|
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria:
|
At Week 16
|
|
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
Prazo: At Week 16
|
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:
|
At Week 16
|
|
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response (in the subset of participants with a PsO BSA ≥ 3% at Baseline)
Prazo: At Week 16
|
PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked). The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from Baseline in PASI score, and was assessed in participants with Baseline psoriasis BSA involvement ≥ 3%. |
At Week 16
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: ABBVIE INC., AbbVie
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- M25-191
- 2024-519291-11 (Substudy 1) (Outro identificador: EU CT)
- 2026-525937-21 (Substudy 2) (Outro identificador: EU CT)
- 2026-527719-41 (Substudy 3) (Outro identificador: EU CT)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Prazo de Compartilhamento de IPD
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Critérios de acesso de compartilhamento IPD
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .